ArticleAnnals of surgical oncology2026
Risk Factors and Prognosis of Peritoneal Metastases in Small Bowel Neuroendocrine Tumor Patients.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: The Challenge of Peritoneal Metastases in Patients with Small Bowel Neuroendocrine Tumors.Annals of surgical oncology · 2026Article
- Options and Considerations in the Management of Peritoneal Disease in Patients with Small Bowel Neuroendocrine Tumors.Current treatment options in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPeritoneal metastases (PM) are common in small bowel neuroendocrine tumors (SBNETs). Risk factors for PM and their impact on disease prognosis is poorly studied.
objectivesThis study reviews 20 years of experience with SBNETs, focusing on identifying risk factors for PM and the long-term oncologic outcomes of cytoreduction.
methodsA retrospective single institutional study was performed from 2005 to 2024 identifying patients with SBNETs who underwent operative resection of their tumors. Primary endpoints were overall survival and progression-free survival, assessed with the Kaplan-Meier method.
resultsIn total, 396 patients were included in the study with rates of metastatic disease and PM of 71.7 and 30.1%, respectively. The presence of liver metastases, female sex, higher T stage, and elevated pancreastatin levels were associated with an increased risk of PM. By Kaplan-Meier analysis, patients with PM had worse overall survival (109 vs. 169 months; p = 0.01) and progression-free survival (42 vs. 75 months, p <0 .01) than those without PM; however, on multivariable analysis, these were not significant. Patients who received cytoreduction of PM had higher rates of major complications (i.e. Clavien-Dindo 3 or 4) than those who did not. Additionally, patients with PM had higher rates of postoperative bowel obstruction, although the greater use of peptide receptor radionuclide therapy in this population may also have contributed.
conclusionsPeritoneal metastases are common in SBNET. Aggressive surgical management is associated with favorable long-term survival, which suggests it should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.